Other languages Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
1.11 ^USD	+2.78%		+49.45%	-20.71%

26/04	Foreign automakers eager for Chinese partners at Beijing auto show	RE
25/04	Battle for 'tech luxury' in China as EVs get smarter - and cheaper	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foreign automakers eager for Chinese partners at Beijing auto show	26/04
Battle for 'tech luxury' in China as EVs get smarter - and cheaper	25/04
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09/04
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Seres Therapeutics Appoints Marella Thorell as Executive Vice President	26/02
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics	24/02
Seres Therapeutics Announces VOWST? Commercial Launch Update and US FDA Fast Track Designation for SER-155	09/01
Huawei's new smart car firm valued up to $35 bln amid advanced stake talks -sources	29/11
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Grégory Behar Resigns from Board of Directors of Seres Therapeutics, Inc	04/23/04
Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023	18/23/18
Seres Therapeutics Gives Inducement Grants to New Employees	09/23/09
Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST	05/23/05
Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™	05/23/05
Seres Therapeutics Receives $125 Million Milestone Payment From Nestle Health After US FDA's Approval of VOWST	31/23/31
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome	09/23/09
Seres Therapeutics Signs New $250 Million Debt Facility With Oaktree Capital Management	27/23/27
Nestlé Unit, Seres Therapeutics' Microbiota-based Drug for Infection Prevention Wins US FDA Nod	27/23/27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Other languages

Filters